Quantification of Brain Atrophy in Early Multiple Sclerosis and Its Clinical Relevance

Basit Öğe Kaydı
dc.contributor.authorUcar, Ceyla Atac
dc.contributor.authorYuceyar, Ayse Nur
dc.contributor.authorKitis, Omer
dc.contributor.authorKose, Timur
dc.contributor.authorEkmekci, Ozgul
dc.contributor.authorSagduyu Kocaman, Ayse
dc.date.accessioned2019-10-27T23:12:55Z
dc.date.available2019-10-27T23:12:55Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective Background: In multiple sclerosis (MS), axonal loss and neurodegeneration occurs early in disease course and may lead to irreversible neurological impairment. We aimed to investigate brain volume loss as an accurate measure of axonal loss and its clinical relevance in early MS. Methods: Twenty MS patients whose first symptoms beginning within the last 2 years were underwent a neurological examination included Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC). Cognitive status of patients was assessed with Paced Auditory Serial Addition Test (PASAT) and Rey Auditory Verbal Learning Test (RAVLT). For processing magnetic resonance imaging (MRI) data, region of interest technique (ROI) and JIM 4.0 software were established. Brain parenchymal fraction (BPF), cerebrospinal fluid (CSF) volume, gray and white matter volumes of brain was determined in MS patients and in control subjects. The relationship between MRI data and demographic, clinical variables was also evaluated. Results: In MS patients, the mean BPF value was significantly lower than controls. BPF also negatively correlated with the duration of disease. 27.3% of the patients have impairment by verbal memory processes tests. We didn't find significant correlation between BPF scores and cognitive performance, and also MSFC/EDSS scores. There was only significant correlation between PASAT scores and white matter volume. Conclusion: Measurement of BPF is a reliable method for brain atrophy that can be used in clinical practice and clinical trials. The atrophy beginning at the early phase of the disease might not cause clinical disability because of cortical reorganization and there might be individual threshold value of axon loss for clinical disability. In order to determine the clinical relevance of brain atrophy, longitudinal MRI studies with cognitive evaluation by comprehensive neurophysiological tests are needed.en_US
dc.identifier.endpage243en_US
dc.identifier.issn1302-1664
dc.identifier.issn1302-1664en_US
dc.identifier.issue2en_US
dc.identifier.startpage233en_US
dc.identifier.urihttps://hdl.handle.net/11454/53281
dc.identifier.volume33en_US
dc.identifier.wosWOS:000389744400005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherJournal Neurological Sciencesen_US
dc.relation.ispartofJournal of Neurological Sciences-Turkishen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMultiple sclerosisen_US
dc.subjectbrain atrophyen_US
dc.subjectbrain parenchymal fractionen_US
dc.titleQuantification of Brain Atrophy in Early Multiple Sclerosis and Its Clinical Relevanceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu